Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 13-93 

AC x 4 followed by CMF x 3 with or without a chemotherapy-free interval, +/- tamoxifen for premenopausal patients with node positive breast cancer who are not suitable for endocrine therapy alone

DESIGN

Design Trial 13-93

Results & Publications


Publications

Study Chairs
Prof. Monica Castiglione - Bern, Switzerland
Dr. Marco Colleoni - Milano, Italy

Statistician
Shari Gelber

Lead Trial Coordinator
Holly Shaw

Director of Data Management
Lynette Blacher

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg10-15@fstrf.org

Date of Activation
May 1993

Date of Closure
August 1, 1999

Targeted Accrual
1225 patients

Final Accrual
1294 patients


Results Publications Results & Publications
Other Pathology


News

18.03.2017:
The next IBCSG Annual Meeting will take place in Vienna, Austria on March 18 and 19, 2017 .

15.03.2017:
15th St.Gallen International Breast Cancer Conference 15-18 March 2017 in Vienna/Austria People

30.09.2016:
Benefiz-Gala mit Spitzenkoch Anton Mosimann Freitag 30. September 2016 im Park Hyatt

All News

 
  Print